What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection

被引:51
|
作者
Khan, Shahid [1 ]
Kessler, Thomas M. [1 ]
Apostolidis, Apostolos [1 ,3 ]
Kalsi, Vinay [1 ]
Panicker, Jalesh [1 ]
Roosen, Alexander [1 ]
Gonzales, Gwen [1 ]
Haslam, Collete [1 ]
Elneil, Sohier
Fowler, Clare J. [1 ]
Dasgupta, Prokar [1 ,2 ]
机构
[1] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London WC1N 3BG, England
[2] Guys & St Thomas Hosp Natl Hlth Serv Fdn Trust, Dept Urol, London, England
[3] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Urol 2, GR-54006 Thessaloniki, Greece
来源
JOURNAL OF UROLOGY | 2009年 / 181卷 / 04期
关键词
urinary bladder; overactive; botulinum toxin type A; recurrence; catheterization; quality of life; TOXIN TYPE-A; QUALITY-OF-LIFE; URINARY-INCONTINENCE; SINGLE-CENTER; DOUBLE-BLIND; ANTICHOLINERGICS; EXPERIENCE; SYMPTOMS; EFFICACY; IMPACT;
D O I
10.1016/j.juro.2008.11.110
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We documented the effects of intradetrusor injections of botulinum neurotoxin type A (Botox (R)) for refractory idiopathic detrusor overactivity so that prospective patients maybe properly informed about possible improvement in quality of life, the duration of interinjection intervals and the risk of clean intermittent self-catheterization. Materials and Methods: A total of 81 consecutive patients with refractory idiopathic detrusor overactivity treated with intradetrusor injections of 200 U botulinum neurotoxin type A at 20 sites per injection course were evaluated in this prospective, nonrandomized, open label cohort study. The primary outcome was changes in quality of life, as assessed by the short form of the Urogenital Distress Inventory and the Incontinence Impact Questionnaire before and after treatment. Secondary outcomes were the interinjection interval and the need for clean intermittent self-catheterization. Results: After intradetrusor botulinum, neurotoxin type A injections there was significant improvement in quality of life, which was sustained after repeat injections. Mean Urogenital Distress Inventory and Incontinence Impact Questionnaire scores decreased from 56 to 26 and 59 to 21 after injection 1 in 81 patients, from 52 to 30 and 51 to 24 after injection 2 in 24, from 40 to 19 and 43 to 17 after injection 3 in 13, from 44 to 17 and 61 to 15 after injection 4 in 6 and from 51 to 17 and 63 to 14 after injection 5 in 4, respectively. The median interinjection interval was 15, 12, 14 and 13 months between injections 1 and 2, 2 and 3, 3 and 4, and 4 and 5, respectively. Considering a post-void residual urine of greater than 100 ml with lower urinary tract symptoms as the indication for clean intermittent self-catheterization, the overall clean intermittent self-catheterization rate after treatment was 43%. Conclusions: Intradetrusor botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity significantly improved quality of life. This effect was sustained after repeat injection. More than 2 of 5 patients with refractory idiopathic detrusor overactivity required clean intermittent self-catheterization after botulinum neurotoxin type A injections and. all prospective patients should be informed about this.
引用
收藏
页码:1773 / 1778
页数:6
相关论文
共 50 条
  • [41] Clinical effects of suburothelial injection of botulinum a toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics
    Kuo, HC
    UROLOGY, 2005, 66 (01) : 94 - 98
  • [42] Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents
    Kuo, HC
    UROLOGY, 2004, 63 (05) : 868 - 872
  • [43] Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children
    Blackburn, S. C.
    Jones, C.
    Bedoya, S.
    Steinbrecher, H. A.
    Malone, P. S.
    Griffin, S. J.
    JOURNAL OF PEDIATRIC UROLOGY, 2013, 9 (06) : 750 - 753
  • [44] A cost effectiveness model for botulinum neurotoxin type A (BoNT/A) in the treatment of patients with detrusor overactivity: preliminary results
    Kalsi, V
    Popat, R
    Odyemi, I
    Borrill, J
    Fowler, CJ
    Dasgupta, P
    BJU INTERNATIONAL, 2005, 95 : 12 - 13
  • [45] Botulinum Neurotoxin Type A with neurogenic Detrusor Overactivity Consensus of the working group neuro- Urology DMGP
    Boethig, R.
    Kaufmann, A.
    Bremer, J.
    Pannek, J.
    Domurath, B.
    UROLOGE, 2014, 53 (09): : 1349 - 1349
  • [46] Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type a for the treatment of neurogenic or idiopathic detrusor overactivity
    Apostolidis, Apostolos
    Jacques, Thomas S.
    Freeman, Alex
    Kalsi, Vinay
    Popat, Roshni
    Gonzales, Gwendoline
    Datta, Soumendra N.
    Ghazi-Noori, Shabnam
    Elneil, Sohier
    Dasqupta, Prokar
    Fowler, Clare J.
    EUROPEAN UROLOGY, 2008, 53 (06) : 1245 - 1253
  • [47] Botulinum toxin type?A injection for neurogenic detrusor overactivity: Clinical outcome in Japanese patients
    Hikita, Katsuya
    Honda, Masashi
    Kawamoto, Bunya
    Panagiota, Tsounapi
    Inoue, Seiya
    Hinata, Nobuyuki
    Muraoka, Kuniyasu
    Takenaka, Atsushi
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (01) : 94 - 99
  • [48] Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children
    Kim, Soo Jeong
    Nang, Quincy
    RoyChoudhury, Arindam
    Kern, Adam
    Sheth, Kunj
    Jacobs, Micah
    Poppas, Dix
    Akhavan, Ardavan
    JOURNAL OF PEDIATRIC UROLOGY, 2022, 18 (03) : 321 - 322
  • [49] PROSPECTIVE RANDOMIZED CONTROLLED TRIAL COMPARING TRIGONAL VERSUS TRIGONE-SPARING INTRADETRUSOR INJECTION OF BOTULINUM TOXIN A FOR REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY
    Manecksha, R. P.
    Cullen, I. M.
    Ahmad, S.
    Mcneill, G. J.
    Mcdermott, T. E. D.
    Flynn, R. J.
    Grainger, R.
    Thornhill, J. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 191 - 191
  • [50] Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore
    Tow, Adela M.
    Toh, Khai-Lee
    Chan, Siew-Pang
    Consigliere, David
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2007, 36 (01) : 11 - 17